An immunological biomarker to predict MTX response in early RA

Objectives The therapeutic goal for patients with rheumatoid arthritis (RA) is clinical remission. This is best achieved by early diagnosis and appropriate therapeutic intervention. RA is associated with dysregulation of T-cell subsets (naïve, regulatory (Treg) and inflammation-related cells (IRC))...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of the rheumatic diseases 2014-11, Vol.73 (11), p.2047-2053
Hauptverfasser:	Ponchel, Frederique, Goëb, Vincent, Parmar, Rekha, El-Sherbiny, Yasser, Boissinot, Marjorie, El Jawhari, Jehan, Burska, Agata, Vital, Edward M, Harrison, Stephanie, Conaghan, Philip G, Hensor, Elizabeth, Emery, Paul
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - immunology Biological Products - therapeutic use Biomarkers - blood Cloning Disease Drug Therapy, Combination Female Flow cytometry Flow Cytometry - methods Humans Immunology Inflammation Male Methotrexate - therapeutic use Middle Aged Patients Pilot Projects Prognosis Proteins Remission Induction Rheumatoid arthritis Rheumatology Sensitivity and Specificity T cell receptors T-Lymphocyte Subsets - drug effects T-Lymphocyte Subsets - immunology Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!